Product Pathways - Growth Factors/Cytokines
Human Interleukin-13 (hIL-13) #8905
|8905LC||25 µg (With Carrier)||---||In Stock||---|
|8905LF||25 µg (Carrier Free)||---||In Stock||---|
|8905SC||5 µg (With Carrier)||---||In Stock||---|
|8905SF||5 µg (Carrier Free)||---||In Stock||---|
Already purchased this product? Write a Review.
Recombinant human IL-13 (hIL-13) Gly21-Asn132 (Accession #X69079) was produced in E. coli at Cell Signaling Technology.
Recombinant hIL-13 does not have a Met on the amino terminus and has a calculated MW of 13,921. DTT-reduced and non-reduced protein migrate as 12 kDa polypeptides with non-reduced protein having slightly greater mobility due to intramolecular cystines. The expected amino-terminal GPVPP of recombinant hIL-13 was verified by amino acid sequencing.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-13. All lots are greater than 98% pure.
The bioactivity of recombinant hIL-13 was determined in a TF-1 cell proliferation assay. The ED50 of each lot is between 0.6-1.2 ng/ml.
The purity of recombinant hIL-13 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hIL-13 and staining overnight with Coomassie Blue.
The proliferation of TF-1 cells treated with increasing concentrations of hIL-13 was assessed. After 72 hour treatment with hIL-13, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.
Western blot analysis of extracts from TF-1 cells, untreated or treated with hIL-13 for 20 minutes, using Phospho-Stat6 (Tyr641) Antibody #9361 (upper) and Stat6 Antibody #9362 (lower).
Less than 0.01 ng endotoxin/1μg hIL-13.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-13. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
IL-13 is produced by T cells and is important in the TH2 response. IL-13 targets include B cells, eosinophils, fibroblasts, mast cells and macrophages (1-3). IL-13 binds specifically to IL-13Rα1 that complexes with IL-4Rα to form the Type II IL-4R. Jak1 and Tyk2 are activated and signal through Stat3 and Stat6 (6). IL-13Rα2 is a different gene product, lacks the intracellular domain, does not complex with IL-4Rα and does not signal (1,6,7). The extracellular domain of IL-13Rα2 is often elevated in diseased states. IL-13 plays key roles in airway hyperresponsiveness (AHR) of allergic asthma (1,4,5) and modulates resistance to parasitic organisms (1).
- Wynn, T.A. (2003) Annu Rev Immunol 21, 425-56.
- Katz, Y. et al. (1995) Clin Exp Immunol 101, 150-6.
- McKenzie, A.N. et al. (1993) Proc Natl Acad Sci USA 90, 3735-9.
- Wills-Karp, M. et al. (1998) Science 282, 2258-61.
- Nakajima, H. and Takatsu, K. (2007) Int Arch Allergy Immunol 142, 265-73.
- Wills-Karp, M. and Finkelman, F.D. (2008) Sci Signal 1, pe55.
- Mentink-Kane, M.M. et al. (2004) Proc Natl Acad Sci USA 101, 586-90.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.